Free Newsletter
No monitoring for Vioxx-takers, court says
Slowly but surely Merck is working its way off the Vioxx hook. First, the successful fight-em-one-by-one strategy, then the big settlement, then a few key overturned verdicts--and now, the New Jersey Supreme Court has ruled that the drugmaker doesn't have to monitor Vioxx patients for future health problems. The 5-1 decision nullifies a class action lawsuit, filed by Vioxx users who don't have symptoms but wanted to be tested for any hidden problems.
The ruling states that patients can't pursue claims for medical monitoring unless they show "harm." Because these plaintiffs had no injuries to report, no harm done--in a legal sense, anyway.
- check out Merck's release
- read the Los Angeles Times story
- see the article in the Star-Ledger
Related Articles:
Vioxx plaintiffs sign on, deal proceeds
Vioxx deal faces pitfalls
Vioxx settlement spawns mega-chatter
Merck takes tough stance on Vioxx
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: